Search Results for "interferon alfa-2b"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for interferon alfa-2b. Results 11 to 13 of 13 total matches.
See also: Intron A
Drugs of Choice for Cancer
Treatment Guidelines from The Medical Letter • Mar 01, 2003 (Issue 7)
+ doxorubicin
Islet cell Streptozocin + doxorubicin Streptozocin + fluorouracil; dacarbazine; interferon alfa ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Telaprevir (Incivek) and Boceprevir (Victrelis) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • Jul 25, 2011 (Issue 1369)
.
STANDARD THERAPY — Peginterferon alfa-2a
(Pegasys) or peginterferon alfa-2b (PegIntron) plus oral ...
Telaprevir (Incivek – Vertex) and boceprevir (Victrelis –
Merck) have been approved by the FDA for oral use in
combination with peginterferon and ribavirin for treatment
of chronic hepatitis C virus (HCV) genotype 1
infection in adults with compensated liver disease.
Both telaprevir and boceprevir were developed specifically
to inhibit the NS3/4A proteases that cleave HCV
encoded polyproteins of the genotype 1 virus.
Simeprevir (Olysio) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • Jan 06, 2014 (Issue 1433)
common genotype in the US and Europe) was
48 weeks of subcutaneously-injected pegylated interferon
alfa ...
The FDA has recently approved 2 new drugs for treatment of chronic hepatitis C virus (HCV) infection. Simeprevir (Olysio – Janssen) is the third oral protease inhibitor to be approved for use in combination with peginterferon and ribavirin for treatment of chronic HCV genotype 1 infection in adults with compensated liver disease. Telaprevir (Incivek) and boceprevir (Victrelis) were approved in 2011 for the same indication. Sofosbuvir (Sovaldi – Gilead), a nucleotide analog polymerase inhibitor that has been approved for use with and without interferon for treatment of multiple HCV...